{"id":250968,"date":"2025-06-03T00:00:00","date_gmt":"2025-06-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidon0158-biopharma-upper-tract-urothelial-carcinoma-epidemiology\/"},"modified":"2026-04-15T09:33:49","modified_gmt":"2026-04-15T09:33:49","slug":"epidon0158-biopharma-upper-tract-urothelial-carcinoma-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0158-biopharma-upper-tract-urothelial-carcinoma-epidemiology-mature-markets\/","title":{"rendered":"Upper Tract Urothelial Carcinoma &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of upper tract urothelial carcinoma (<abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the developed world.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr> per year?<\/li>\n<li>How will improvements in survival change the number of people living with a diagnosis of <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr>?<\/li>\n<li>How will a declining risk of recurrence change the number of first-line drug-treatment opportunities for <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr>?<\/li>\n<li>Of all people diagnosed with <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr>, how many in each how many in each country in the developed world are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr data-abbreviation-entity=\"10739\" title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.<\/p>\n<p>Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr> patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases of <abbr data-abbreviation-entity=\"10288\" title=\"upper tract urothelial carcinoma \">UTUC<\/abbr>.<\/li>\n<li>Diagnosed incident cases of <abbr data-abbreviation-entity=\"10288\" title=\"upper tract urothelial carcinoma \">UTUC<\/abbr> by stage at diagnosis.<\/li>\n<li>Diagnosed incident cases of <abbr data-abbreviation-entity=\"10288\" title=\"upper tract urothelial carcinoma \">UTUC<\/abbr> by muscle-invasiveness at diagnosis.<\/li>\n<li>Diagnosed locally recurrent incident cases of <abbr data-abbreviation-entity=\"10288\" title=\"upper tract urothelial carcinoma \">UTUC<\/abbr>.<\/li>\n<li>Diagnosed\u00a0bladder recurrent incident cases of <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr>.<\/li>\n<li>Diagnosed bladder recurrent incident cases of <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr> by muscle-invasiveness.<\/li>\n<li>Diagnosed incident cases of metastatic recurrent <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr>.<\/li>\n<li>Drug-treatable non-muscle-invasive <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr>.<\/li>\n<li>Drug-treatable localized and resectable locally advanced <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr>.<\/li>\n<li>Diagnosed unresectable locally advanced or metastatic <abbr title=\"upper tract urothelial carcinoma \">UTUC<\/abbr> 1<sup>st<\/sup> line drug-treatable population.<\/li>\n<\/ul>\n<p>\u2026 and more (details available on request).<\/p>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250968","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-solid-tumors","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250968\/revisions"}],"predecessor-version":[{"id":574007,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250968\/revisions\/574007"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}